Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-03-01FDA Approved: XANAX XR — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for XANAX XR (alprazolam) filed by Viatris Specialty LLC.
-
FDA approval · 2021-02-16FDA Approved: PAROXETINE — Original Application (Westminster Pharmaceuticals, LLC)
The FDA approved Westminster Pharmaceuticals' generic paroxetine (PAROXETINE) via an Original Application (ANDA213485). It covers indication…
-
CLINICAL_TRIALS trial_result · 2021-02-12Clinical Trial Update: Brain Stimulation & Generalized Anxiety Study [Phase 4]
Phase 4 trial update on brain stimulation for anxiety disorders, currently active but not recruiting.
-
FDA approval · 2021-02-09FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approves a supplemental application for buspirone hydrochloride from Mylan Pharmaceuticals Inc. This is an ANDA-related approval for a g…
-
FDA approval · 2021-02-08FDA Approved: DIAZEPAM — Supplemental Application (Natco Pharma USA LLC)
FDA approved a supplemental application for Diazepam (generic) from Natco Pharma USA LLC under an ANDA. The action confirms approval of the …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-02-06FDA Approved: PAXIL — Supplemental Application (Apotex Corp)
FDA approved a supplemental application for Paxil (paroxetine hydrochloride) submitted by Apotex Corp.
-
FDA approval · 2021-02-05FDA Approved: CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA supplemental approval for a generic chlordiazepoxide and amitriptyline hydrochloride product from Mylan Pharmaceuticals.
-
FDA approval · 2021-02-05FDA Approved: ALPRAZOLAM — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Alprazolam submitted by Mylan Pharmaceuticals, contributing to the existing approval for thi…
-
FDA approval · 2021-02-05FDA Approved: XANAX XR — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for XANAX XR (alprazolam) from Viatris Specialty LLC. The action involves changes to the product…
-
FDA approval · 2021-02-05FDA Approved: DIAZEPAM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for diazepam from Hikma Pharmaceuticals USA Inc. to market a generic diazepam product.
-
FDA approval · 2021-02-05FDA Approved: ALPRAZOLAM — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for alprazolam by Actavis Pharma, Inc., enabling a generic alprazolam product.
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder [Phase 3]
A Phase 3 trial comparing pregabalin to venlafaxine XR and placebo for generalized anxiety disorder has completed.
-
FDA approval · 2020-12-30FDA Approved: DULOXETINE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' supplemental application for duloxetine (ANDA204343), enabling the continued marketing of the gener…
-
FDA approval · 2020-11-03FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for venlafaxine hydrochloride (generic) under ANDA076565, enabling it…
-
CLINICAL_TRIALS trial_result · 2020-10-23Clinical Trial Update: Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities [Phase 4]
Phase 4 trial update on the efficacy of an SNRI for generalized anxiety disorder and comorbid conditions.
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of CD-008-0045 in patients with generalized anxiety disorder.
-
FDA approval · 2020-10-21FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved the generic venlafaxine hydrochloride (venlafaxine) under Original Application for the treatment of major depressive disorder, …
-
FDA approval · 2020-10-01FDA Approved: CYMBALTA — Supplemental Application (Eli Lilly and Company)
FDA approves a supplemental application for Cymbalta (duloxetine hydrochloride) submitted by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2020-09-29Clinical Trial Update: The Modular Protocol for Mental Health (MPMH) [Phase 1, Phase 2]
Phase 1 and Phase 2 study of the Modular Protocol for Mental Health (MPMH) completed; investigates treatment approaches for multiple mental …
-
CLINICAL_TRIALS trial_result · 2020-08-24Clinical Trial Update: А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder [Phase 2]
Phase 2 dose-finding trial for CD-008-0045 in generalized anxiety disorder has completed, assessing efficacy and safety.
-
CLINICAL_TRIALS trial_result · 2020-08-05Clinical Trial Update: Online Treatments for Mood and Anxiety Disorders in Primary Care [Phase 2, Phase 3]
Phase 2/3 clinical trial update evaluating online treatments for mood and anxiety disorders in primary care; completed.
-
FDA approval · 2020-07-28FDA Approved: DOXEPIN HYDROCHLORIDE — Original Application (Contract Pharmacal Corp.)
FDA approved an original application for doxepin hydrochloride, a generic product from Contract Pharmacal Corp., with labeling for major dep…
-
FDA approval · 2020-07-21FDA Approved: PAROXETINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for Paroxetine hydrochloride from Apotex Corp., enabling continued marketing of a generic product.
-
CLINICAL_TRIALS trial_result · 2020-07-14Clinical Trial Update: Efficacy and Safety Study of a IMSS Developed Phytopharmaceutical for the Treatment of Anxiety. [Phase 2]
Phase 2 trial update evaluating an IMSS-developed phytopharmaceutical for generalized anxiety disorder; efficacy and safety data not yet ava…
-
CLINICAL_TRIALS trial_result · 2020-06-22Clinical Trial Update: GATE: Generalized Anxiety - A Treatment Evaluation [NA]
A completed clinical trial update for GATE evaluating treatment in Generalized Anxiety Disorder; results posted in 2020.